Regulus RNAi Candidate Can Reduce HCV Treatment To Four Weeks

Although it is on FDA clinical hold to resolve safety concerns about jaundice, RG-101 has shown the ability to significantly reduce the length – and perhaps cost – of HCV therapy when combined with current direct-acting antivirals.

BOSTON – New data on Regulus Therapeutics Inc.’s RNA interference drug RG-101, which had been submitted for presentation at the American Association for the Study of Liver Diseases meeting, show that the Phase II candidate has the efficacy to help it find a commercially viable route into the hepatitis C market, if the company can get past a clinical hold placed by FDA earlier this year.

The Phase II data showing that RG-101 in combination with direct-acting antiviral (DAA) therapy can reduce duration of treatment for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category